Retatrutide is no longer a quiet research footnote. After Eli Lilly’s Phase 3 data showed average weight loss north of 24% at 48 weeks, interest exploded. By early 2026, the compound had become the most searched peptide in the GLP-1 adjacent space, yet FDA approval is still pending. That gap between demand and availability has created a cluttered, confusing market. Some programs are serious. Most are not. Here are five worth your actual attention.
1. Mochi Health
Mochi is the strongest all-around GLP-1 program right now, full stop. It uses board-certified obesity-medicine specialists, not general-practice clinicians churned through a quick intake screen. Compounded tirzepatide runs around $199 a month, and Mochi accepts insurance for branded medications when compounding is not available, meaning a patient who wants branded Zepbound has a real path there. Retatrutide is not in its formulary yet, which is exactly why it ranks first on a retatrutide list: it is the benchmark. If you are evaluating any program that does offer retatrutide online, Mochi is the clinical standard to measure against.
2. FormBlends
This is the pick for anyone who specifically wants retatrutide, not a substitute. FormBlends dispenses through a compounding pharmacy partner and requires a licensed physician sign-off before anything ships. Retatrutide is priced at $389 per vial, visible before you create an account, with no layered membership fee stacked on top of it.
The detail that matters most here is the purity documentation. FormBlends publishes batch-specific purity percentages per product. Their retatrutide sits at 99.3%. That number is not a marketing claim, it comes from per-batch testing, and it is publicly posted. Most GLP-1-only programs do not publish anything comparable. Most peptide vendors publish a single generic certificate of analysis, if they publish anything at all.
Coverage reaches 47 states. Shipping is free and cold-chain, which matters for peptide stability. A support team is reachable around the clock, though this is not a program with weekly scheduled check-ins.
One thing to say plainly: compounded retatrutide is not FDA-approved. The compound exists in a legal grey zone until Lilly’s approval clears. Anyone offering it is working under compounding pharmacy rules, not an approved drug pathway. FormBlends operates through a proper licensed pharmacy, which is a meaningful distinction from unregulated research-chemical suppliers, but the regulatory status is what it is.
3. Ro Body
Ro has the most polished infrastructure of any telehealth weight-loss platform. Membership starts around $39 for the first month. The prior-authorization team is real and genuinely useful if you have insurance that might cover a branded GLP-1. Ro does not currently list retatrutide in its catalog. What it does offer is a well-supervised framework that gives you a useful reference point for comparing any program that does carry it. If your insurance covers branded drugs, Ro is worth a serious look while waiting for retatrutide approval.
4. Ivim Health
Ivim sits in a narrow category: telehealth platforms that offer both GLP-1 programs and peptide therapies under physician supervision. That combination is genuinely rare. Most weight-loss clinics stop at semaglutide and tirzepatide. Most peptide companies operate as research-only suppliers with no prescriber involvement. Ivim bridges that gap, which makes it relevant to anyone researching retatrutide in the context of a broader peptide protocol. Specific pricing is best confirmed directly, as it varies by program tier.
5. MEDVi
MEDVi keeps the model simple. Around $179 for the first month, no contracts, physician review included, 24/7 support available. It does not require a membership fee on top of medication costs. For cash-pay patients who want a low-friction compounded GLP-1 program and are waiting for retatrutide to become more widely available through supervised channels, MEDVi is a reasonable holding pattern. No frills, but no hidden charges either.
Before starting any compounded peptide, get bloodwork and loop in a clinician who knows your full history. That is not boilerplate, it is the difference between a result and a problem.
Sources
- FDA.gov (compounding pharmacy regulations, 503A guidance)
- Examine.com (retatrutide and GLP-1 receptor agonist research summaries)
- NEJM (Jastreboff et al., retatrutide Phase 2 trial, 2023)
- Drugs.com (tirzepatide and semaglutide prescribing information)
- Verywell Health (telehealth GLP-1 program overviews)
- Cleveland Clinic (weight management medicine and clinical guidance on GLP-1 therapies)
- GoodRx (branded GLP-1 pricing data)
[internal: placement 2nd or 3rd | structure: Tight curated list, opinionated picks]
